Kaya Pai Panandiker

Kaya Pai Panandiker has served as Neumora’s Chief Commercial Officer since January 2024, and has more than 20 years of experience in the pharmaceutical industry, including the commercial launches of TRINTELLIX (vortioxetine) and REXULTI (brexpiprazole) for major depressive disorder (MDD) and schizophrenia. 

Kaya brings extensive commercial strategy and execution expertise to Neumora, having led the launch of multiple neuropsychiatry products throughout her distinguished career. Prior to joining Neumora, Kaya served as head of commercial at Cerevel Therapeutics and general manager, neuroscience at Lundbeck US. During her time at Lundbeck, she led commercialization efforts for its neuroscience franchise, achieving blockbuster sales.  

Kaya holds a master’s in public policy from University of Chicago and a bachelor’s in American studies from University of Wisconsin Madison.